| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Acalabrutinib | Acalabrutinib Impurity 1 | VL5060003 | View CAS 2230757-47-6 |
| Acalabrutinib | Acalabrutinib Impurity 1-D4 | DVE0012 | View |
| Acalabrutinib | Acalabrutinib Impurity 10 | VE0011654 | View |
| Acalabrutinib | Acalabrutinib Impurity 11 | VE007042 | View CAS 2490433-97-9 |
| Acalabrutinib | Acalabrutinib Impurity 18 | VE0010035 | View CAS 1148-11-4 |
| Acalabrutinib | Acalabrutinib Impurity 19 | VE0010036 | View CAS 939412-86-9 |
| Acalabrutinib | Acalabrutinib Impurity 2 | VE0011635 | View |
| Acalabrutinib | Acalabrutinib Impurity 20 | VE0010037 | View CAS 1418307-17-1 |
| Acalabrutinib | Acalabrutinib Impurity 21 | VE0010038 | View CAS 1418307-18-2 |
| Acalabrutinib | Acalabrutinib Impurity 22 | VE0010040 | View CAS 1420478-87-0 |
| Acalabrutinib | Acalabrutinib Impurity 3 | VE0011636 | View |
| Acalabrutinib | Acalabrutinib Impurity 4 | VE0011637 | View |
| Acalabrutinib | Acalabrutinib Impurity 5 | VE0011638 | View |
| Acalabrutinib | Acalabrutinib Impurity 6 | VE0011641 | View |
| Acalabrutinib | Acalabrutinib Impurity 7 | VE0011643 | View |
| Acalabrutinib | Acalabrutinib Impurity 8 | VE0011652 | View |
| Acalabrutinib | Acalabrutinib Impurity 9 | VE0011653 | View |
| Acalabrutinib | Acalabrutinib N-Oxide | VE0011655 | View |
| Acalabrutinib | Acalabrutinib-D4 | DVE0011 | View |
Acalabrutinib Related Compound
The Bruton tyrosine kinase inhibitor acalabrutinib is used to treat mantle cell lymphoma, chronic lymphocytic leukaemia, and small lymphocytic lymphoma.
References
- Byrd, John C., et al. “Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia.” Blood, vol. 137, no. 24, June 2021, pp. 3327–38, https://doi.org/10.1182/blood.2020009617.
- “Facebook.” National Cancer Institute, Cancer.gov, 2017, www.cancer.gov/about \cancer/treatment/clinical-trials/intervention/acalabrutinib?redirect=true.
- Jaradat, Dania. “Acalabrutinib (Calquence) – AmeriPharma Specialty Care.” AmeriPharma Specialty Care, 17 Nov. 2021, ameripharmaspecialty.com/acalabrutinib-calquence/.
FAQ’s
Is acalabrutinib a chemotherapy medication?
Calquence is another commercial name for acalabrutinib . It is a chemotherapeutic and antineoplastic (anticancer) medication that belongs to the tyrosine kinase inhibitor class (TKI). TKIs inhibit the enzyme tyrosine kinase, preventing cell growth and division.
How long does acalabrutinib therapy last?
Acalabrutinib was given for a median of 52 months (range, 0.2-60 months), with an overall median time on therapy of 53 months.
Is acalabrutinib considered a targeted therapy?
Acalabrutinib is a targeted medication that inhibits a protein called bruton tyrosine kinase (BTK), which aids in cell survival and growth.
